Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
- 문서 유형
- 연구출판물 · 리뷰논문
- 등재
- KCIScopus
- 저널 순위
- Scopus Q2
- 저널
- Journal of Pathology and Translational Medicine53(3) · pp.153 · 2019
- 피인용
- Scopus 10KCI 3
- FWCI (Scopus)
- 0.27
- ISSN
- 2383-7837
저자
- 신동훈제1저자Department of Pathology, Pusan National University School of Medicine, Yangsan
- 심효섭Department of Pathology, Yonsei University College of Medicine, Seoul
- 김태정Department of Hospital Pathology, College of Medicine, Catholic University of Korea, Seoul
- 박혜성Department of Pathology, Ewha Womans University Mokdong Hospital, Seoul
- 최윤라Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
- 김완섭Department of Pathology, Konkuk University School of Medicine, Seoul
- 김루시아Department of Pathology, Inha University School of Medicine, Incheon
- 장선희Department of Pathology, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang
- 송준선Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul
- 김효진Department of Pathology, Seoul National University Bundang Hospital, Seongnam
- 한정호Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
- 이창훈Department of Pathology, Pusan National University School of Medicine, Yangsan
- 이건국Department of Pathology, National Cancer Center, Goyang, Korea
- 장세진교신저자Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul
초록
Liquid biopsy for detection of mutation from circulating tumor DNA is a new technology which is attractive in that it is non-invasive. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) is an effective first line drug for advanced non-small cell lung cancer patients who harbor activating EGFR mutation. During the course of treatment, resistance against TKI arises which can be contributed to EGFR T790M mutation in about 50–60% of patients. Third generation TKI may overcome the resistance. In patients who cannot undergo tissue biopsy due to variable reasons, liquid biopsy is an excellent alternative for the detection of EGFR T790M mutation. However, this relatively novel method requires standardization and vigorous quality insurance. Thus, a standard set of guideline recommendations for liquid biopsy for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of provisional guideline recommendations that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.
키워드
Carcinomanon-small-cell lungEpidermal growth factor receptorT790MCirculating tumor DNALiquid biopsy
식별자
- Scopus EID
- 2-s2.0-85066491607
- KCI
- ART002465683



로그인
연구물 목록으로